Most recently chief technology officer for Vyteris, Mr Hartounian previously served as a director and CEO of Protagenic Therapeutics, a biotechnology company he founded in 2006 to treat neurological disorders.
A long-time member of the Vyteris team, Mr Himy transitions from vice president of finance to CFO at the company. He previously was also principal accounting officer and controller for Vyteris.
Vyteris also reaffirmed its strategy to pursue additional collaborative development and licensing opportunities with pharmaceutical companies with existing drug lines to enhance performance and to potentially extend valuable patent protection.